Maaisha Osman

5 days ago | insidehealthpolicy.com | Maaisha Osman

The Trump administration’s push to revive the controversial “most favored nation” (MFN) pricing policy -- alongside ongoing uncertainty around tariffs and Medicare drug price negotiations -- is creating deep uncertainty for the future of generic and biosimilar drug development in the United States, Association for Accessible Medicines (AAM) President and CEO John Murphy told Inside Health Policy in a Monday (June 2) interview.

5 days ago | insidehealthpolicy.com | Maaisha Osman

FDA’s decision not to appeal a federal court ruling that invalidated its attempt to regulate laboratory-developed tests (LDTs) under the medical device framework signals the Trump administration’s intention not to defend the rule -- a move that falls in line with the previous Trump administration’s move to block FDA from regulating LDTs.

5 days ago | insidehealthpolicy.com | Maaisha Osman

HHS is requesting $27.5 billion for the National Institutes of Health and $4.3 billion for the Centers for Disease Control and Prevention in its detailed fiscal 2026 budget request to Congress released Friday (May 30) -- mirroring the Trump administration’s “skinny budget” proposal earlier in the month for a roughly 40% cut to both agencies -- while emphasizing certain chronic disease research and making deep reductions to global health and emergency preparedness programs.

1 week ago | insidehealthpolicy.com | Maaisha Osman

Pharmaceutical companies spent more than $5 billion on television advertising last year and often used “manipulative” tactics to market psychiatric drugs for children, according to the recently unveiled Make America Health Again (MAHA) Commission report.

1 week ago | insidehealthpolicy.com | Maaisha Osman

The status of one of President Donald Trump’s key tariff tools is being disputed in court, but the president still has several legal avenues to target pharmaceutical imports -- most notably through Section 232 of the Trade Expansion Act, which allows tariffs on national security grounds.